# US 2008/0188549 A1 · Composition for Preventing and/or Treating Metabolic Syndrome and Insulin Resistance Syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188549 A1
- Document ID: US20080188549A1
- Status: Published application
- Kind: A1
- Application number: 11/815,896
- Filed: 2006-02-08
- Published: 2008-08-07
- Earliest claimed: 2005-02-09
- Assignees: Kaneka Corporation
- Inventors: Hozumi Tanaka; Shinichi Yokota; Misuzu Tsukagawa; Tatsumasa Mae; Minpei Kuroda; Yoshihiro Mimaki
- Web page: https://patentgrep.com/patent/US20080188549A1

## CPC

- C07D 311/28: with aromatic rings attached in position 2 only
- A61K 31/121: acyclic
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 45/78: Separation; Purification; Stabilisation; Use of additives
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention has its object to provide a specific compound derived from a naturally occurring substance, and a composition for the prevention and/or treatment of metabolic syndrome and insulin resistance syndrome which comprises that as an active ingredient, easily and efficiently. The present invention relates to a composition for the prevention and/or treatment of metabolic syndrome and a composition for the prevention and/or treatment of insulin resistance syndrome, each of which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof.

## Claims

### Claim 1

A compound represented by the formula (1) or a salt or ester thereof.

### Claim 2

A compound represented by the formula (2) or a salt or ester thereof.

### Claim 3

A PPARγ ligand agent
which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 4

A composition for the prevention and/or treatment of metabolic syndrome,
which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof.
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 5 (depends on 4)

The composition for the prevention and/or treatment of metabolic syndrome according to claim 4
wherein the compound represented by the formula (4) is a compound represented by the formula (6).

### Claim 6 (depends on 4)

The composition for the prevention and/or treatment of metabolic syndrome according to claim 4
wherein the compound represented by the formula (5) is the compound represented by the formula (2).

### Claim 7 (depends on 4)

The composition for the prevention and/or treatment of metabolic syndrome according to claim 4
which comprises at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof, the content thereof being not lower than 0.0000001% by weight but lower than 100% by weight.

### Claim 8

A composition for the prevention and/or treatment of insulin resistance syndrome,
which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 9 (depends on 8)

The composition for the prevention and/or treatment of insulin resistance syndrome according to claim 8
wherein the compound represented by the formula (4) is a compound represented by the formula (6).

### Claim 10 (depends on 8)

The composition for the prevention and/or treatment of insulin resistance syndrome according to claim 8
wherein the compound represented by the formula (5) is the compound represented by the formula (2).

### Claim 11 (depends on 8)

The composition for the prevention and/or treatment of insulin resistance syndrome according to claim 8
which comprises at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof, the content thereof being not lower than 0.0000001% by weight but lower than 100% by weight.

### Claim 12

The composition according to 4
which is to be eaten or drunk.

### Claim 13

The composition according to 4
which is used for medical or medicinal purposes.

### Claim 14

The composition according to 4
which is applied to domestic animals or pets.

### Claim 15

A method for the prevention and/or treatment of metabolic syndrome,
which comprises using at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 16

A use of at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof for the preparation of a composition for the prevention and/or treatment of metabolic syndrome:
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 17

A method for the prevention and/or treatment of insulin resistance syndrome,
which comprises using at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 18

A use of at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof for the preparation of a composition for the prevention and/or treatment of insulin resistance syndrome:
[In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring; the other represents H, OH, OCH3 or CHO.]

### Claim 19 (depends on 5)

The composition for the prevention and/or treatment of metabolic syndrome according to claim 5
which comprises at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof, the content thereof being not lower than 0.0000001% by weight but lower than 100% by weight.

### Claim 20 (depends on 9)

The composition for the prevention and/or treatment of insulin resistance syndrome according to claim 9
which comprises at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof, the content thereof being not lower than 0.0000001% by weight but lower than 100% by weight.
